Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

被引：6
|
作者：
Guercio, Brendan John [1 ]
Pietzak, Eugene J. [1 ]
Brown, Samantha [1 ]
Chen, Jie-Fu [1 ]
Peters, Vanessa [1 ]
Regazzi, Ashley Marie [1 ]
Aggen, David Henry [1 ]
Donahue, Timothy F. [1 ]
Goh, Alvin C. [1 ]
Cha, Eugene K. [1 ]
Donat, S. Machele [1 ]
Dalbagni, Guido [1 ]
Bochner, Bernard H. [1 ]
Funt, Samuel Aaron [1 ]
Bajorin, Dean F. [1 ]
Iyer, Gopa [1 ]
Ostrovnaya, Irina [1 ]
Al-Ahmadie, Hikmat A. [1 ]
Rosenberg, Jonathan E. [1 ]
Teo, Min Yuen [1 ]
机构：
[1] US Natl Inst Health, Conquer Canc Fdn Amer Soc Clin Oncol, Bristol Myers Squibb, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
498
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) plus tremelimumab (T) plus enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial
    Drakaki, A.
    Powles, T. B.
    Wang, Y.
    Bupathi, M.
    Joshi, M.
    Fleming, M. T.
    de Liano Lista, A. Gomez
    Morales Barrera, R.
    Pili, R.
    Boulos, S.
    Shrestha, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1140 - S1140
  • [42] Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase 11 study.
    Plimack, Elizabeth R.
    Hoffman-Censits, Jean H.
    Kutikov, Alexander
    Greenberg, Richard E.
    Bilusic, Marijo
    Chen, David Y. T.
    Viterbo, Rosalia
    Lallas, Costas D.
    Lin, Jianqing
    Trabulsi, Edouard John
    Geynisman, Daniel M.
    Kelly, William Kevin
    Smaldone, Marc C.
    Devarajan, Karthik
    Adaire-Halenda, Beth
    Cione, Charlotte
    Kilpatrick, Deborah
    Duncan, Gail
    Wong, Yu-Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
    Jain, Rohit K.
    Yang, Yuanquan
    Chadha, Juskaran
    Chatwal, Monica Sheila
    Kish, Julie Ann
    Raymond, Sarah
    Rembisz, Jennifer
    Jameel, Ghazal
    Mustasam, Arfa
    Poehlman, Trey
    Fan, Wenyi
    Kim, Youngchul
    Dhillon, Jasreman
    Alemany, Carlos A.
    Mortazavi, Amir
    Zhang, Jingsong
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [44] Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC)
    Balar, Arjun Vasant
    Iyer, Gopa
    Milowsky, Matthew I.
    Huang, William C.
    Woods, Michael
    Donat, S. Machele
    Herr, Harry W.
    Dalbagni, Guido
    Bochner, Bernard H.
    Ostrovnaya, Irina
    Al-Ahmadie, Hikmat
    Rose, Tracy Lynn
    Riches, Jamie Cathleen
    Kania, Brooke Elizabeth
    Regazzi, Ashley Marie
    Mccoy, Asia S.
    Delbeau, Daniela
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [45] A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) plus tremelimumab (T) plus enfortumab vedotin (EV) or D plus EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).
    Powles, Thomas
    Drakaki, Alexandra
    Teoh, Jeremy Yuen-Chun
    Grande, Enrique
    Fontes-Sousa, Mario
    Porta, Camillo
    Wu, Esther
    Goluboff, Erik T.
    Ho, Svetlana
    Hois, Stephan
    Gupta, Ashok Kumar
    Catto, James W. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [46] Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
    Matsubara, Nobuaki
    Mukai, Hirofumi
    Naito, Yoichi
    Nezu, Masahiko
    Itoh, Kuniaki
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (04) : 310 - 317
  • [47] Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence
    Narain, Tushar Aditya
    Tosh, Jyoti Mohan
    Gautam, Gagan
    Talwar, Harkirat Singh
    Panwar, Vikas Kumar
    Mittal, Ankur
    Mandal, Arup Kumar
    UROLOGY, 2021, 154 : 8 - 15
  • [48] The neoadjuvant management of muscle-invasive bladder cancer (MIBC) in Canada: A national survey of urologists
    Sridhar, Srikala S.
    Chi, Kim N.
    North, Scott A.
    Black, Peter C.
    Wood, Lori
    Hsu, Tina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [49] Neoadjuvant chemotherapy (NAC) with dose-dense gemcitabine/cisplatin (DDGC) in localized muscle-invasive bladder cancer (MIBC).
    Tsironis, George
    Zakopoulou, Roubini
    Koutsoukos, Konstantinos
    Tzanis, Kimon
    Varkarakis, John
    Papatsoris, Athanasios
    Stravodimos, Kostas
    Kostouros, Efthymios
    Fragkoulis, Charalampos
    Choreftaki, Theodosia
    Filippiadis, Dimitrios
    Fontara, Sofia
    Dellis, Athanasios
    Ntai, Sparti
    Zygogianni, Anna
    Ntoumas, Konstantinos
    Constantinides, Constantinos A.
    Korkolopoulou, Penelope
    Dimopoulos, Meletios A.
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Hiromi Murasawa
    Takuya Koie
    Chikara Ohyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Ikuya Iwabuchi
    Masaru Ogasawara
    Toshiaki Kawaguchi
    International Journal of Clinical Oncology, 2017, 22 : 159 - 165
12345